Download MendeleyFragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors.
de Vicente, J., Tivitmahaisoon, P., Berry, P., Bolin, D.R., Carvajal, D., He, W., Huang, K.S., Janson, C., Liang, L., Lukacs, C., Petersen, A., Qian, H., Yi, L., Zhuang, Y., Hermann, J.C.(2015) ACS Med Chem Lett 6: 1019-1024
- PubMed: 26396691 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00251
- Primary Citation Related Structures:
5C5P, 5C5Q, 5C5R - PubMed Abstract:
Tankyrase activity has been linked to the regulation of intracellular axin levels, which have been shown to be crucial for the Wnt pathway. Deregulated Wnt signaling is important for the genesis of many diseases including cancer. We describe herein the discovery and development of a new series of tankyrase inhibitors. These pyranopyridones are highly active in various cell-based assays. A fragment/structure based optimization strategy led to a compound with good pharmacokinetic properties that is suitable for in vivo studies and further development.
- Discovery Chemistry, Non-clinical Safety, Discovery Technologies, and Discovery Oncology, Small Molecule Research, Pharma Research & Early Development, Hoffmann-La Roche Inc. , pRED, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
Organizational Affiliation:
